SCHEMBL4432292

SCHEMBL4432292

NOP(=O)(Oc1cccnc1Cl)C(Cc1ccccc1)NS(=O)(=O)c1cccs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
TSHR P16473 1/20 0.39
ALDH1A1 P00352 6/20 0.38
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
USP2 O75604 1/20 0.37
GLA P06280 1/20 0.37
PKM P14618 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4E B2RXH2 1/20 0.36
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
PLAT P00750 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4432295 0.86 MAPT (0.42) MAPTTP53THRBTSHRALDH1A1
SCHEMBL4423285 0.84 KDM4E (0.38) MAPTTP53THRBTSHRALDH1A1
SCHEMBL4433532 0.81 POLB (0.38) MAPTTP53TSHRALDH1A1HTT
Ammonia Solution, Strong SCHEMBL4423287 0.74 RECQL (0.38) MAPTTP53THRBTSHRALDH1A1
SCHEMBL5596825 0.73 MAPT (0.48) MAPTTP53THRBTSHRALDH1A1
SCHEMBL6908900 0.73 CYP2D6 (0.46) TP53TSHRALDH1A1HTTPKM
SCHEMBL5596466 0.71 TSHR (0.55) MAPTTP53THRBTSHRALDH1A1
Ammonia Solution, Strong SCHEMBL4433535 0.71 POLB (0.40) MAPTTP53TSHRALDH1A1HTT
SCHEMBL4422634 0.71 CYP2D6 (0.43) TP53TSHRALDH1A1HTTPKM
SCHEMBL6526208 0.70 CYP2D6 (0.42) TP53TSHRALDH1A1HTTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514556-B2 Inhibitors of β-lactamase METHYLGENE INC. (CA) 2009-04-07 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-20060105999-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2006-05-18 US disclosed
US-7030103-B2 Sulfonamidomethyl phosphonate inhibitors of β-lactamase METHYLGENE, INC. (CA) 2006-04-18 US disclosed
EP-1194436-B1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2005-11-30 EP disclosed
US-6921756-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-07-26 US disclosed
US-6884791-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-04-26 US disclosed
US-20050043276-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2005-02-24 US disclosed
WO-2004048393-A2 NOVEL INHIBITORS OF β-LACTAMASE METHYLGENE, INC. (CA) 2004-06-10 WO disclosed
US-20040082546-A1 Novel Inhibitors of beta-lactamase METHYLGENE, INC. 2004-04-29 US disclosed
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-03-25 US disclosed
US-20040029836-A1 Novel inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-02-12 US disclosed
EP-1194436-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE Methylgene, Inc. (CA) 2002-04-10 EP disclosed
WO-2001002411-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE METHYLGENE INC. (CA) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043276-A1 Novel inhibitors of beta-lactamase MGAM, LSS, CYP51A1 MAPT 3410/4885TP53 4702/4885THRB 2911/4885
US-20040029836-A1 Novel inhibitors of beta-lactamase LSS, MGAM, COASY MAPT 3535/4885TP53 4706/4885THRB 3021/4885
US-20060105999-A1 Novel inhibitors of beta-lactamase LSS, MGAM, LCT MAPT 3445/4885TP53 4739/4885THRB 3001/4885
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase PGLS, MGAM, STS MAPT 3423/4885TP53 4185/4885THRB 3484/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 MAPT 3410/4885TP53 4702/4885THRB 2911/4885
US-20040082546-A1 Novel Inhibitors of beta-lactamase LSS, MGAM, COASY MAPT 3363/4885TP53 4733/4885THRB 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.